Barata PC, Rini BI (2017) Treatment of renal cell carcinoma: current status and future directions [J]. CA: A Cancer J Clin 67(6):507–524

Google Scholar 

Bray F, Laversanne M, Sung H, Global cancer statistics et al (2022) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer J Clin 2024:caac.21834

Google Scholar 

Znaor A, Lortet-Tieulent J, Laversanne M et al (2015) International variations and trends in renal cell carcinoma incidence and mortality [J]. European Urol 67(3):519–530

Article  Google Scholar 

Riaz IB, He H, Ryu AJ et al (2021) A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma[J]. European Urol 80(6):712–723

Article  CAS  Google Scholar 

Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. New England J Med 380(12):1116–1127

Article  CAS  Google Scholar 

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update - PubMed[EB/OL]. /2024–04–10. https://pubmed.ncbi.nlm.nih.gov/35346519/.

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. New England J Med 378(14):1277–1290

Article  CAS  Google Scholar 

Singla N, Freifeld Y, Ghandour RA et al (2020) Rational approaches to treatment duration with immunotherapy in metastatic renal cell carcinoma[J]. Eur Urol Focus 6(1):31–33

Article  PubMed  Google Scholar 

Robert C, Marabelle A, Herrscher H et al (2020) Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm [J]. Nature Rev Clin Oncol 17(11):707–715

Article  CAS  Google Scholar 

Waterhouse DM, Garon EB, Chandler J et al (2020) Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153[J]. J Clin Oncol 38(33):3863–3873

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedlaender A, Kim C, Addeo A (2020) Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic[J]. Front Oncol 10:862

Article  PubMed  PubMed Central  Google Scholar 

McDermott DF, Drake CG, Sznol M et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab [J]. Journal of Clin Oncol 33(18):2013–2020

Article  CAS  Google Scholar 

Tzeng A, Tzeng TH, Ornstein MC (2021) Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis[J]. J Immunother Cancer 9(10):e003473

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer 45(2):228–247

Article  CAS  PubMed  Google Scholar 

Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines [J]. J Clin Oncol 2(3):187–193

Article  CAS  PubMed  Google Scholar 

Motzer R, Alekseev B, Rha S-Y et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. New England J Med 384(14):1289–1300

Article  CAS  Google Scholar 

Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. New England J Med 384(9):829–841

Article  CAS  Google Scholar 

Yan XQ, Ye MJ, Zou Q et al (2024) 2024 Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study[J]. Annals Oncol 35(2):190–199

Article  CAS  Google Scholar 

Powles T, Plimack ER, Soulières D et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol 21(12):1563–1573

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Porta C, Eto M et al (2024) Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study[J]. J Clin Oncol 42(11):1222–1228

Article  CAS  PubMed  Google Scholar 

ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426[EB/OL]. /2024–04–13. https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-kidney-cancer/144965-asco-2023-pembrolizumab-axitinib-versus-sunitinib-as-first-line-therapy-for-advanced-clear-cell-rcc-5-year-analysis-of-keynote-426.html.

Herbst RS, Garon EB, Kim D-W et al (2021) Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC[J]. J Thoracic Oncol 16(10):1718–1732

Article  CAS  Google Scholar 

Robert C, Ribas A, Schachter J et al (2019) Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209–003 study[J]. Lancet Oncol 20(9):1239–1251

Article  CAS  PubMed  Google Scholar 

Gettinger S, Horn L, Jackman D et al (2018) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. J Clin Oncol 36(17):1675–1684

Article  CAS  PubMed  Google Scholar 

Jansen Y, Rozeman EA, Foppen MG et al (2017) Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression[J]. J Clin Oncol 35(15_suppl):9539–9539

Article  Google Scholar 

Arlauckas SP, Garris CS, Kohler RH et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy[J]. Sci Trans Med 9(389):eaal3604

Article  Google Scholar 

Ramos P, Bentires-Alj M (2015) Mechanism-based cancer therapy: resistance to therapy, therapy for resistance[J]. Oncogene 34(28):3617–3626

Article  CAS  PubMed  Google Scholar 

Baik CS, Rubin EH, Forde PM et al (2017) Immuno-oncology clinical trial design: limitations, challenges, and opportunities[J]. Clin Cancer Res 23(17):4992–5002

Article  PubMed  PubMed Central  Google Scholar 

Robert C, Ribas A, Hamid O et al (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma[J]. J Clin Oncol 36(17):1668–1674

Article  CAS  PubMed  Google Scholar 

Hamid O, Robert C, Daud A et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J]. Annals Oncol 30(4):582–588

Article  CAS  Google Scholar